Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilsotolimod plus Ipilimumab in Metastatic Melanoma (ILLUMINATE-204)
NCT02644967Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- Dec 2015
- Primary completion
- Feb 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of tilsotolimod in melanoma, sponsored by Aceragen, Inc.. Started Dec 2015; status: completed.
02
Drugs
tilsotolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02644967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644967.